Boston Scientific names Joe Fitzgerald chief operating officer effective Jan. 1, 2027
Boston Scientific said Joe Fitzgerald, currently executive vice president and group president of Cardiovascular, will become executive vice president and chief operating officer effective January 1, 2027. The company also plans three new reportable segments effective the same date, and it named Mark Bickel as chief accounting officer effective March 1, 2027, succeeding Emily Woodworth.
Key points
- Fitzgerald's offer letter sets an annual base salary of $1,050,000 and a bonus target of 110% of base salary.
- His 2027 annual equity award has a total grant date fair value of $7,000,000, expected in February 2027.
- Three reportable segments take effect January 1, 2027: Interventional Therapies, Rhythm Solutions and MedSurg.
- Mark Bickel, 49, will become Senior Vice President, Global Accounting Controller and Chief Accounting Officer on March 1, 2027.
The filing
Written by AI on Nov 8, 2026, 1:42 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 07, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.